C2S2

  • Research type

    Research Study

  • Full title

    Chronic Coronary Syndrome Snapshot Study

  • IRAS ID

    345406

  • Contact name

    Emilie Soriano

  • Contact email

    registries@escardio.org

  • Clinicaltrials.gov Identifier

    2024-A01053-44, N° ID RCB (French authority)

  • Duration of Study in the UK

    1 years, 4 months, 13 days

  • Research summary

    Coronary artery disease (CAD) refers to the presence of atherosclerotic plaques in the coronary arteries, which can be non-obstructive or obstructive. It represents a major cause of morbidity, mortality, hospitalization and health expenditure in Europe.
    The European Society of Cardiology (ESC) plays a pivotal role in advancing the field of cardiology by regularly updating and disseminating clinical practice guidelines. In 2019, the ESC released the latest iteration of its guidelines for the diagnosis and management of Chronic Coronary Sydrome (CCS).
    The Chronic Coronary Syndrome Snapshot (C2S2) study aims to evaluate the current adherence to the 2019 ESC Guidelines on CCS among healthcare professionals and identify potential barriers and facilitators to guideline implementation.
    The results can inform targeted interventions and educational programs aimed at enhancing adherence to the 2019 ESC guidelines for CCS, ultimately improving patient outcomes and the quality of care for individuals with CCS.
    C2S2 will enrol adult patients who sign a written informed consent form and with confirmed or suspected diagnosis of CCS amoung these 6 following CCS categories: i) patients with suspected CAD and stable anginal symptoms and/or dyspnoea; ii) patients with new onset of heart failure or left ventricular dysfunction and suspected CAD; iii) asymptomatic and symptomatic patients with stabilised symptoms within one year after an acute coronary syndrome, or patients with recent revascularisation; iv) asymptomatic and symptomatic patients beyond one year after initial diagnosis or revascularisation; v) patients with angina and suspected vasospastic or microvascular disease; vi) asymptomatic subjects in whom CAD is detected at screening
    To ensure the representativeness of all the potential healthcare settings, not only hospitals but also outpatient clinics, primary care practices, and healthcare providers in the community will be involved.
    The study is designed with 2 visits: one at enrollment and one follow up visit at 3 months to assess the current practice.

  • REC name

    North East - Tyne & Wear South Research Ethics Committee

  • REC reference

    24/NE/0151

  • Date of REC Opinion

    9 Aug 2024

  • REC opinion

    Favourable Opinion